Amgen Completes Onyx Pharmaceuticals Tender Offer
socalTECH
OCTOBER 1, 2013
Thousand Oaks-based Amgen reported this morning that it has completed its tender offer for Onyx Pharmaceuticals , and now expects its acquisition to complete today. Amgen is paying $125 per share in cash for publicly held Onyx Pharmaceuticals, a developer of biopharmaceuticals for treating cancer. READ MORE>>.
Let's personalize your content